

# Clinical Trial Network Enrolling Patients in Houston for Clinical Trial of Promising New Treatment for Alzheimer's

*Individuals with memory problems encouraged to learn more about study*

HOUSTON, TEXAS, UNITED STATES, September 14, 2022 / EINPresswire.com/ -- Clinical Trial Network is initiating a clinical trial for a promising new investigational treatment for Alzheimer's disease (AD) in Houston.



The Phase I study will determine the safety and tolerability of a single intravenous (IV) dose and multiple IV doses of ACU193. We are asking individuals who have memory problems to consider participating in the trial to assist in evaluating this medication for the treatment of Alzheimer's disease. There is no cost to participate. Acumen Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for AD, is sponsoring the clinical trial.

“

We're excited to open this trial in Houston to study ACU193 for the treatment of Alzheimer's disease.”

*Dr. Berrios*

ACU193 targets amyloid-beta oligomers and is a different

approach to treating Alzheimer's disease than currently approved medications. ACU193 is designed to locate and bind to amyloid-beta oligomers – proteins that build up in the brain in people with Alzheimer's disease. These proteins are thought to be involved in Alzheimer's disease symptoms and progression.

The trial site, located at 7080 Southwest Fwy, Houston, TX 77074, is led by principal investigator Dr. Nelson Berrios, MD at Clinical Trial Network. Patients who believe they qualify for the study are asked to call 713.484.6947 or email [Lamjad@cntntexas.com](mailto:Lamjad@cntntexas.com) to learn more.

“We're excited to open this trial in Houston to study ACU193 for the treatment of Alzheimer's disease,” Dr. Berrios said. “If you or a loved one is experiencing memory problems, contact us to find out more about the study. More than 6 million Americans are living with Alzheimer's

disease. New, safe and effective treatments are needed more than ever. Participating in clinical trials is one way members of our community can help make a difference.”

#### Key Eligibility Criteria:

- Age 55 to 90 years of age.
- Have memory problems that might be a sign of mild cognitive impairment (usually mild memory loss) or mild dementia. The underlying cause of these memory problems may or may not be due to Alzheimer’s disease. Tests given within the study will help to determine this.
- Have a caregiver or study partner; someone who knows the participant very well, who is willing to assist with participation in the study and can attend the study visits with the participant.
- The staff at the study center will explain the complete list of requirements.

This study is the first time ACU193 will be given to people. As all drugs and medical procedures carry a risk of side effects, it is possible that participants may experience some discomfort or other reactions from use of ACU193. The study staff will explain these potential risks before potential participants decide whether to participate in the study. The safety of participants will be closely monitored throughout the study.

Study participants will receive a full diagnostic work-up, including an amyloid PET scan and MRI that can provide a more accurate diagnosis and help guide future treatment options. After finishing this study, participants may consider participating in future studies of ACU193 in which all participants could receive ACU193 at some point in the study.

#### About ACU193

ACU193 is a monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble A $\beta$ Os, which Acumen believes are the most toxic and pathogenic form of A $\beta$  relative to A $\beta$  monomers and amyloid plaques. Soluble A $\beta$ Os have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble A $\beta$ Os, ACU193 aims to directly address what a growing body of evidence indicates is a primary underlying cause of the neurodegenerative process in AD.

#### About Clinical Trial Network

Clinical Trial Network (CTN) is a reliable and dedicated research facility that offers quality research study options to Houston area volunteers. Conducted by renowned and experienced research professionals, CTN is a diverse and multidisciplinary clinical research center: each and every staff member strives to further the understanding of neural, pain, and behavioral disorders.

Media Contact:

Layla Amjad  
Clinical Trial Network  
+1 713-484-6947

[email us here](#)

Visit us on social media:

[Facebook](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/588896255>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.